138 related articles for article (PubMed ID: 37869929)
1. Pharmacokinetics and tissue distribution study of two novel quinazoline PI3K/mTOR dual-inhibitors, potential anticancer agents.
Chen J; Bian X; Zhang S; Yang G
Pak J Pharm Sci; 2023 Sep; 36(5):1527-1542. PubMed ID: 37869929
[TBL] [Abstract][Full Text] [Related]
2. Study on the interaction of two quinazoline derivatives as novel PI3K/mTOR dual inhibitors and anticancer agents to human serum albumin utilizing spectroscopy and docking.
Chen J; Bian X; Zhang S; Yang G
Luminescence; 2023 Mar; 38(3):260-268. PubMed ID: 36648974
[TBL] [Abstract][Full Text] [Related]
3. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
8. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947.
Liu X; Liang X; LeCouter J; Ubhayakar S; Chen J; Cheng J; Lee T; Lubach J; Nonomiya J; Shahidi-Latham S; Quiason C; Solon E; Wright M; Hop CECA; Heffron TP
Drug Metab Dispos; 2020 May; 48(5):408-419. PubMed ID: 32132091
[TBL] [Abstract][Full Text] [Related]
14. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Siddesh A; Sriram D; Zakkula A; Kumar R; Dittakavi S; Zainuddin M; Trivedi RK; Mullangi R
Biomed Chromatogr; 2021 Apr; 35(4):e5015. PubMed ID: 33125719
[TBL] [Abstract][Full Text] [Related]
15. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
16. Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
Faes S; Santoro T; Troquier L; De Souza Silva O; Dormond O
Biochem Biophys Res Commun; 2019 Jun; 513(3):546-552. PubMed ID: 30981504
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors.
Raj A; Kumar A; Singh AK; Singh H; Thareja S; Kumar P
Anticancer Agents Med Chem; 2023; 23(9):1013-1047. PubMed ID: 36650627
[TBL] [Abstract][Full Text] [Related]
19. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
20. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]